Management of ocular surface inflammation in Sjogren syndrome
Management of ocular surface inflammation in Sjogren syndrome
复制标题
DOI：
10.1097/ico.0b013e31812f6782
复制
发表时间：
2007-10-01
期刊：
影响因子：
2.8
通讯作者：
Yun, Pil-Young
中科院分区：
文献类型：
--
作者：
Hyon, Joon Young;Lee, Yun Jong;Yun, Pil-Young
目的：评价抗炎治疗治疗原发性干燥综合征的临床疗效。方法：本研究纳入38例原发性干燥综合征患者。干燥综合征的诊断是根据欧美共识组的分类标准进行的。首次就诊时测量荧光素染色评分、孟加拉玫瑰染色评分、Schirmer 测试评分、泪膜破裂时间以及包括眼表疾病指数 (OSDI) 和视觉模拟量表 (VAS) 评分在内的功能参数。抗炎治疗包括局部皮质类固醇、局部自体血清、局部环孢素A。从主观症状和客观体征（包括Schirmer-1试验、破裂时间、玫瑰孟加拉评分、荧光素评分）来评价抗炎治疗的临床疗效。结果：干燥综合征患者的玫瑰孟加拉评分高于非干燥综合征患者（P < 0.05）。 OSDI 评分与荧光素评分的相关性优于与 VAS 评分的相关性。 70% 的原发性干燥综合征患者的主观症状通过抗炎治疗得到改善。抗炎治疗显着改善视力和荧光素评分，但不影响Schinner评分、泪膜破裂时间或玫瑰孟加拉评分。结论：原发性干燥综合征的抗炎治疗显着改善主观症状和客观眼部体征；然而，我们没有发现抗炎治疗会增加干燥综合征患者泪液产生的证据。
Purpose: To evaluate the clinical efficacy of anti-inflammatory therapy in the management of primary Sjogren syndrome.Methods: Thirty-eight patients with primary Sjogren syndrome were included in this study. The diagnosis of Sjogren syndrome was made on the basis of the classification criteria of the American-European Consensus Group. Fluorescein staining score, rose-bengal staining score, Schirmer test score, tear film breakup time, and functional parameters including ocular surface disease index (OSDI) and visual analog scale (VAS) score were measured at the first visit. Anti-inflammatory therapy included topical corticosteroids, topical autologous serum, and topical cyclosporin A. The clinical efficacy of anti-inflammatory treatment was evaluated in terms of subjective symptorns and objective signs (including Schirmer-1 test, breakup time, rose-bengal score, and fluorescein score).Results: Patients with Sjogren syndrome had higher rose-bengal scores than patients with non-Sjogren dry eye (P < 0.05). The OSDI score showed better correlation with fluorescein score than with VAS score. Subjective symptoms improved with anti-inflammatory treatment in 70% of patients with primary Sjogren syndrome. Antiinflammatory treatment provided significant improvement in visual acuity and fluorescein score but did not affect Schinner score, tear breakup time, or rose-bengal score.Conclusions: Anti-inflammatory therapy in primary Sjogren syndrome significantly improved subjective symptoms and objective ocular signs; however, we did not find evidence that anti-inflammatory treatment increases tear production in patients with Sjogren syndrome.